Fibrillation and tachycardia detection

• US 5,366,487 A
• Filed: 11/04/1993
• Issued: 11/22/1994
• Est. Priority Date: 03/09/1992
• Status: Expired due to Fees

• Current Assignee: Angeion Corporation (Niterra Co., Ltd.)
• Original Assignee: Angeion Corporation (Niterra Co., Ltd.)
• Inventors: Kroll, Mark W., Adams, Theodore P.
• Primary Examiner(s): Cohen, Lee S.
• Assistant Examiner(s): Parker, Marianne
• Application Number:
  US08/147,464
• Time in Patent Office: 383 Days
• Field of Search: 128/695, 128/696, 128/700, 128/702, 128/705, 607/5, 607/6, 607/9, 607/14
• US Class Current: 607/5
• CPC Class Codes: A61N 1/3621 for treating or preventing abnormally high heart rate
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/3956 Implantable devices for applying electric shocks to the heart, e.g. for cardioversion

Abstract

Providing a sensitive, prompt, and accurate indication of both ventricular fibrillation and monomorphic ventricular tachycardia is the aim of this invention. The invention employs electrical voltage-versus-time signals produced by the heart, these observed from two or more locations. By well-known signal-processing techniques, these signals are reduced to pulses of standardized height and duration, each derived from a prominent feature of the waveform for each heart period, such as its leading edge, in the process eliminating the irrelevant information in the waveform, but retaining the feature that is most relevant in the present context, namely, its precise time of occurrence. The invention then uses further standard electronic techniques to determine the amount of delay between the corresponding pulses in two such pulse trains, in the process distinguishing between monomorphic ventricular tachycardia and more benign conditions. It is a further straightforward matter of signal analysis to determine coincidence rate as a fraction of total pulse rate, which in the normal heart approaches unity (100%), while in the fibrillating heart is much lower, thus diagnosing ventricular fibrillation. The present invention is hence able to trigger a defibrillating-discharge decision, or a cardioversion-discharge in the prior case, much more reliably than has been possible in the prior art.

Claims

1. An improved fibrillation and tachycardia detection system for a cardioversion-defibrillation system including means for detecting whether a patient'"'"'s heart is in a normal cardiac rhythm or an abnormal cardiac rhythm and, in response to detection of an abnormal cardiac rhythm, means for automatically delivering an electrical countershock therapy of greater than about 1.0 joules of electrical energy to treat the abnormal cardiac rhythm, the improvement comprising:

local detection means for sensing a local electrical signal representing cardiac activity in one of a plurality of local areas of the patient'"'"'s heart, each local area having a local electrical signal;

global detection means for sensing a global electrical signal representing cardiac activity in a global area of the patient'"'"'s heart, the global area including the plurality of the local areas such that the global electrical signal represents an electrical average of the local electrical signals of the plurality of local areas;

means for successively measuring a delay value between a first time when the local electrical signal meets a predetermined trigger criteria and a second time when the global electrical signal meets the predetermined trigger criteria;

means for storing and comparing a series of the delay values to detect whether the patient'"'"'s heart is in the abnormal cardiac rhythm and should be treated by the cardioversion defibrillation system or whether the patient'"'"'s heart is in the normal cardiac rhythm and should not be treated by the cardioversion defibrillation system.

2. The detection system of claim 1 wherein the global detection means comprises at least one far-field electrode.

3. The detection system of claim 2 wherein the far-field electrode is an epicardial-patch electrode.

4. The detection system of claim 2 wherein the far-field electrode is a subcutaneous-patch electrode.

5. The detection system of claim 2 wherein the far-field electrode is an implanted housing which houses the cardioversion defibrillation system as an implantable device.

6. The detection system of claim 1 wherein the means for storing and comparing comprises:

means for storing the series of delay values;

means for determining a mean for the series of the delay values;

means for determining a standard deviation for the series of the delay values;

means for indicating detection of a ventricular fibrillation if the standard deviation is greater than a first predetermined value, the ventricular fibrillation to be treated by delivery of a defibrillation countershock therapy; and

means for indicating detection of a monomorphic tachycardia if the mean is greater than a second predetermined value, the monomorphic tachycardia to be treated by delivery of a cardioversion countershock therapy.

7. The detection system of claim 1 wherein the means for successively measuring comprises:

first pulse detector means for generating a first digital pulse when the local electrical signal meets the predetermined trigger criteria;

second pulse detector means for generating a second digital pulse when the global electrical signal meets the predetermined trigger criteria; and

means for measuring a time period between the first and second digital pulse to generate the delay value.

8. The detection system of claim 7 wherein the means for measuring the time period comprises a clocked shift register.

9. The detection system of claim 7 wherein the means for measuring the time period comprises a clocked counter.

10. The detection system of claim 7 wherein the means for storing and comparing comprises:

means for delaying the first digital pulse by a predetermined amount such that a delayed first digital pulse and the second digital pulse are coincident when the patient'"'"'s heart is in the normal cardiac rhythm;

means for sensing the coincidence over the series of the delays between the delayed first digital pulses and the second digital pulses to detect whether the patient'"'"'s heart is in a ventricular fibrillation; and

means for determining if an average of the time periods over the series of delays is greater than a predetermined value to detect whether the patient'"'"'s heart is in a monomorphic tachycardia.

11. The detection system of claim 1 wherein the local detection means comprises a pair of point electrodes spaced apart from one another by less than about 1 centimeter and the global detection means comprises a pair of point electrodes spaced apart from one another by greater than about 1 centimeter.

12. A method of fibrillation and tachycardia detection for a cardioversion-defibrillation device capable of automatically delivering an electrical countershock therapy of greater than 1.0 joules of electrical energy to treat a patient'"'"'s heart in response to detection of an abnormal cardiac rhythm, the method comprising the device-implemented steps of:

(a) providing a local electrical signal representing cardiac activity in one of a plurality of local areas of the patient'"'"'s heart, each local area having a local electrical signal;

(b) providing a global electrical signal representing cardiac activity in a global area of the patient'"'"'s heart including the plurality of local areas such that the global electrical signal represents an electrical average of the local electrical signals of the plurality of local areas;

(c) detecting when either the local electrical signal or the global electrical signal meet a predetermined trigger condition and starting a delay timer;

(d) detecting when the one of either the local electrical signal of the global electrical signal not detected in step (c) meets the predetermined trigger condition and stopping the delay timer;

(e) storing a delay value from the delay timer for each of a series of trigger conditions;

(f) comparing the series of delay values to detect whether the patient'"'"'s heart is in the abnormal cardiac rhythm and should be treated by the cardioversion defibrillation system or whether the patient'"'"'s heart is in the normal cardiac rhythm and should not be treated by the cardioversion defibrillation system.

13. The method of claim 12 wherein step (f) comprises:

(f1) determining a mean for the series of the delay values;

(f2) determining a standard deviation for the series of the delay values;

(f3) indicating detection of a ventricular fibrillation if the standard deviation is greater than a first predetermined value, the ventricular fibrillation to be treated by delivery of a defibrillation countershock therapy; and

(f4) indicating detection of a monomorphic tachycardia if the mean is greater than a second predetermined value, the monomorphic tachycardia to be treated by delivery of a cardioversion countershock therapy.